Gossamer Bio (NASDAQ:GOSS) Upgraded at Leerink Partners

Posted by Brian Himes on Jul 31st, 2026

Leerink Partners upgraded shares of Gossamer Bio (NASDAQ:GOSS – Free Report) from a market perform rating to an outperform rating in a research report released on Tuesday, Marketbeat.com reports. Leerink Partners currently has $1.00 target price on the stock.

GOSS has been the subject of a number of other research reports. Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research report on Monday. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $3.20.

Get Our Latest Analysis on Gossamer Bio

Gossamer Bio Stock Performance

Shares of Gossamer Bio stock opened at $0.18 on Tuesday. The company has a market cap of $41.85 million, a P/E ratio of -0.23 and a beta of 2.04. Gossamer Bio has a one year low of $0.11 and a one year high of $3.87. The firm has a fifty day moving average of $0.18 and a two-hundred day moving average of $0.75.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last released its earnings results on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.95 million for the quarter, compared to the consensus estimate of $4.67 million. As a group, equities analysts predict that Gossamer Bio will post -0.39 earnings per share for the current year.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors have recently made changes to their positions in the stock. Kalehua Capital Management LLC purchased a new position in shares of Gossamer Bio in the 1st quarter valued at about $3,363,000. State Street Corp lifted its stake in shares of Gossamer Bio by 139.7% in the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock valued at $28,864,000 after purchasing an additional 5,427,302 shares during the period. Corient Private Wealth LLC boosted its holdings in Gossamer Bio by 19,123.7% during the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares in the last quarter. Millennium Management LLC boosted its holdings in Gossamer Bio by 629.3% during the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock worth $9,519,000 after buying an additional 3,123,081 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Gossamer Bio by 4,196.2% during the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock worth $7,579,000 after buying an additional 2,814,824 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.